Gina Kolata

Lung cancer is still a leading cause of cancer death, but that rate is half what it was in the 1990s, partly because newly developed treatments are working.

Targeted gene therapies are highly effective at stopping cancers, but the very abundance of the treatments, plus cost and sluggish change, are hindering access.

The gene is found predominantly in Southern Appalachia and may be one of the most powerful cancer-risk mutations ever found.

Cardiologists are struggling to figure out why a drug that should have prevented heart attacks didn’t work at all.

Doctors were hopeful the drug, which was being tested in a large clinical trial by Novartis, was going to be a powerful new tool to fight heart disease.

In a key clinical trial, patients who got the pill, daraxonrasib, lived twice as long as those who got chemotherapy.

Through sheer determination, Neena Nizar has become the first patient in a clinical trial testing a treatment for her disease — one so rare it affects just 30 people worldwide.

The drug targeted inflammation, and its shocking failure has experts questioning whether inflammation really does cause heart disease.

The vast majority of cases begin in the fallopian tubes — and removing them can reduce the risk by nearly 80 percent.

A new nonprofit wants to streamline gene therapy for diseases often avoided by pharmaceutical companies — making treatment more like a routine procedure than a bespoke drug.